Atiprimod

DRUG5 trials

Sponsors

Callisto Pharmaceuticals, M.D. Anderson Cancer Center

Conditions

Advanced CancerMultiple MyelomaNeuroendocrine Carcinoma

Phase 1

Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

CompletedNCT00086216

Callisto PharmaceuticalsMultiple Myeloma

Start: 2004-05-31End: 2007-11-30Updated: 2007-12-21

An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer

Callisto PharmaceuticalsAdvanced Cancer

Start: 2005-03-31End: 2007-03-31Target: 61Updated: 2006-12-05

Study of Atiprimod Treatment for Patients With Advanced Cancer

TerminatedNCT00430014

M.D. Anderson Cancer CenterAdvanced Cancer

Start: 2005-03-31End: 2012-02-29Updated: 2012-02-15

Phase 2

Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

CompletedNCT00388063

Callisto PharmaceuticalsNeuroendocrine Carcinoma

Start: 2006-10-31End: 2007-09-30Updated: 2007-12-21

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

CompletedNCT00663429

Callisto PharmaceuticalsNeuroendocrine Carcinoma

Start: 2007-11-30End: 2010-03-31Updated: 2011-08-31